Disturbing: Puberty Blocking Drug Companies Refuse to Conduct Safety Trials

Manufacturers that dominate the U.S. market for puberty blockers refuse to conduct safety trials on their frequently prescribed off-label use to treat gender dysphoria in adolescents. Endo International plc and AbbVie Inc have repeatedly declined to conduct safety tests on the puberty blocking drug Lupron, according to a new report by Reuters.

Left-wing news outlet Reuters published data on Thursday about the rising number of children and adolescents adopting a transgender identity and seeking medical interventions. Among the shocking revelations is that between 2017 to 2021, 17,683 of the 121,882 children ages 6 to 17 diagnosed with gender dysphoria received puberty blockers or cross-sex hormones. Despite such widespread adoption for the drug’s off-label use, the drug’s manufacturers refuse to conduct safety trials for their use in treating gender dysphoria in adolescents.

Dr Brad Miller, division director of pediatric endocrinology at the University of Minnesota Medical School and M Health Masonic Children’s Hospital, and “several other doctors,” told Reuters they had “repeatedly asked” AbbVie, Endo, and other manufacturers of puberty blockers to seek FDA approval for the drugs in treating gender dysphoria in children and to conduct clinical trials to establish their safety. “They said the companies always declined,” reported Reuters.

“They would say it would cost a lot of money to get approval,” Miller said of the drug manufacturers’ refusal. “And they were not interested in going there because (transgender treatment) was a political hot potato.” (Read more from “Disturbing: Puberty Blocking Drug Companies Refuse to Conduct Safety Trials” HERE)

Delete Facebook, Delete Twitter, Follow Restoring Liberty and Joe Miller at gab HERE.